Our Faculty

Kiran Turaga, MD MBBS

University of Pittsburgh Medical Center
Fellowship

H. Lee Moffitt Cancer & Research Institute
Fellowship

Creighton University Medical Center
Residency

Creighton University Medical Center
Internship

All India Institute of Medical Sciences
MD

Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease.
Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth K, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 2020 Nov 24.
PMID: 33234578

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
White MG, Schulte JJ, Xue L, Berger Y, Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK, Eng OS. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 2020 Oct 26.
PMID: 33100328

Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy.
Reizine N, Peterson B, Moya S, Wang Y, Tan YCYH, Eng OS, Bilimoria M, Lengyel E, Turaga K, Catenacci DVT. Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. JCO Precis Oncol. 2020; 4.
PMID: 33215053

Ampullary adenocarcinoma: the current state of adjuvant therapies.
Vining CC, Schuitevoerder D, Turaga KK. Ampullary adenocarcinoma: the current state of adjuvant therapies. Hepatobiliary Surg Nutr. 2020 Oct; 9(5):647-649.
PMID: 33163515

Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma.
Berger Y, Schuitevoerder D, Vining CC, Alpert L, Fenton E, Hindi E, Liao CY, Shergill A, Catenacci DVT, Polite BN, Eng OS, Turaga KK. Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Ann Surg Oncol. 2020 Sep 05.
PMID: 32892267

Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?
Alter R, Turaga K, Lengyel E. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? JAMA Netw Open. 2020 08 03; 3(8):e2014184.
PMID: 32840618

Appendiceal Mucinous Neoplasm: Nurse Education About a Rare and Complex Disease.
Kamm AM, Turaga KK. Appendiceal Mucinous Neoplasm: Nurse Education About a Rare and Complex Disease. Clin J Oncol Nurs. 2020 08 01; 24(4):409-414.
PMID: 32678367

Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement.
Liu JB, Schuitevoerder D, Vining CC, Berger Y, Turaga KK, Eng OS. Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement. Ann Surg Oncol. 2020 Dec; 27(13):5039-5046.
PMID: 32729047

HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin.
Morgan R, Parsad S, Turaga KK, Eng OS. HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin. Basic Clin Pharmacol Toxicol. 2020 Dec; 127(6):551-553.
PMID: 32623784

Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States.
Schuitevoerder D, Sherman SK, Izquierdo FJ, Eng OS, Turaga KK. Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States. Ann Surg Oncol. 2020 09; 27(9):3097-3102.
PMID: 32632884

View All Publications